Santaris Formally Unveils California Subsidiary, Marking Company's Foray into the US
September 17, 2009
Santaris Formally Unveils California Subsidiary, Marking Company's Foray into the US
The subsidiary will be located in San Diego, Calif., and will be led by Santaris Chief Development Office Arthur Levin, who was previously senior vice president of drug development at antisense shop Isis Pharmaceuticals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News - People in the News: Soren Tulstrup, Henrik Stage
May 31, 2012 / Gene Silencing News - With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News - Santaris to Present Phase IIa Data on HCV Drug
April 19, 2012 / Gene Silencing News - Isis Opposes Santaris Bid to Throw out Patent-Infringement Suit
March 29, 2012 / Gene Silencing News